Peijia Medical Future Growth

Future criteria checks 2/6

Peijia Medical is forecast to grow earnings and revenue by 71.3% and 29.2% per annum respectively. EPS is expected to grow by 70.6% per annum. Return on equity is forecast to be -2.4% in 3 years.

Key information

71.3%

Earnings growth rate

70.6%

EPS growth rate

Medical Equipment earnings growth40.8%
Revenue growth rate29.2%
Future return on equity-2.4%
Analyst coverage

Low

Last updated28 Dec 2024

Recent future growth updates

Recent updates

Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge

Sep 09
Why Investors Shouldn't Be Surprised By Peijia Medical Limited's (HKG:9996) 26% Share Price Surge

Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%

Jul 17
Risks Still Elevated At These Prices As Peijia Medical Limited (HKG:9996) Shares Dive 30%

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%

Mar 28
More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 27%

More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%

Jan 22
More Unpleasant Surprises Could Be In Store For Peijia Medical Limited's (HKG:9996) Shares After Tumbling 29%

Estimating The Intrinsic Value Of Peijia Medical Limited (HKG:9996)

Dec 05
Estimating The Intrinsic Value Of Peijia Medical Limited (HKG:9996)

Does Peijia Medical (HKG:9996) Have A Healthy Balance Sheet?

Oct 22
Does Peijia Medical (HKG:9996) Have A Healthy Balance Sheet?

Calculating The Fair Value Of Peijia Medical Limited (HKG:9996)

Aug 04
Calculating The Fair Value Of Peijia Medical Limited (HKG:9996)

Is Peijia Medical (HKG:9996) A Risky Investment?

May 29
Is Peijia Medical (HKG:9996) A Risky Investment?

Getting In Cheap On Peijia Medical Limited (HKG:9996) Is Unlikely

May 10
Getting In Cheap On Peijia Medical Limited (HKG:9996) Is Unlikely

Are Investors Undervaluing Peijia Medical Limited (HKG:9996) By 40%?

Jan 17
Are Investors Undervaluing Peijia Medical Limited (HKG:9996) By 40%?

Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt

Oct 05
Despite Lacking Profits Peijia Medical (HKG:9996) Seems To Be On Top Of Its Debt

A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)

Aug 29
A Look At The Fair Value Of Peijia Medical Limited (HKG:9996)

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Mar 16
We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth

Nov 26
We Think Peijia Medical (HKG:9996) Can Easily Afford To Drive Business Growth

We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Jul 30
We're Hopeful That Peijia Medical (HKG:9996) Will Use Its Cash Wisely

Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?

May 05
Is Peijia Medical Limited (HKG:9996) Worth HK$28.3 Based On Its Intrinsic Value?

Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?

Mar 03
Could The Peijia Medical Limited (HKG:9996) Ownership Structure Tell Us Something Useful?

Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price

Jan 27
Peijia Medical Limited's (HKG:9996) Intrinsic Value Is Potentially 43% Above Its Share Price

We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth

Dec 23
We Think Peijia Medical (HKG:9996) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

SEHK:9996 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20271,645N/A-48N/A2
12/31/20261,027-14-141724
12/31/2025811-86-252-244
12/31/2024623-170-346-954
6/30/2024517-252-305-155N/A
3/31/2024479-322-602-369N/A
12/31/2023441-393-900-583N/A
9/30/2023399-460-921-609N/A
6/30/2023357-528-942-635N/A
3/31/2023304-468-760-506N/A
12/31/2022251-408-579-376N/A
9/30/2022227-449-684-441N/A
6/30/2022204-491-790-506N/A
3/31/2022170-533-710-471N/A
12/31/2021137-574-629-436N/A
9/30/2021106-515-446-327N/A
6/30/202176-455-262-217N/A
3/31/202157-1,262-235-199N/A
12/31/202039-2,069-207-181N/A
9/30/202033-2,128-203-180N/A
6/30/202028-2,187-200-179N/A
3/31/202023-1,360-158-141N/A
12/31/201919-532-116-103N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9996 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 9996 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 9996 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 9996's revenue (29.2% per year) is forecast to grow faster than the Hong Kong market (7.5% per year).

High Growth Revenue: 9996's revenue (29.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 9996 is forecast to be unprofitable in 3 years.


Discover growth companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 03:38
End of Day Share Price 2025/01/09 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Peijia Medical Limited is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sharon ShiBOCI Research Ltd.
Yuan GaoChina International Capital Corporation Limited
Bo YuChina International Capital Corporation Limited